Key Publications
In collaboration with researchers and thought leaders around the world, Guardant Health uses scientific expertise and cutting-edge innovation to help drive precision oncology forward.
Key Publications by Topic:
Cancer Screening
- The American Journal of Gastroenterology: Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk
- Journal of Medical Economics: Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence
- New England Journal of Medicine: A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
- Gut: Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence
- PLOS One: “I was screaming hallelujah”: Patient and provider perceptions of blood-based testing for colorectal cancer screening
- Annals of Oncology: High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
- DDW 2023 Presentation: Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer Screening in an Average Risk Population
- ASCO 2022 Poster: Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity
- DDW 2022 Oral Presentation: Multi-modal blood-based colorectal cancer screening is a viable colorectal cancer screening option – a prospective study
- AACR 2022 Oral Abstract: Development of a highly-sensitive targeted cell-free DNA epigenomic assay for early-stage multi-cancer screening
- ACG 2021 Oral Abstract: Multimodal circulating tumor DNA blood-based colorectal cancer screening test demonstrates clinically meaningful sensitivity across multiple clinical parameters
- ASCO 2021 Abstract: Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC)
- ASCO 2021 Poster: Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer
- AACR 2020 Abstract: Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer
- AACR 2020 Poster: Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer (CRC)
- AACR 2020 Abstract: Understanding patient-reported barriers to colorectal cancer screening: A literature review
- AACR 2020 Poster: Understanding patient-reported barriers to colorectal cancer screening: A literature review
- AACR 2019 Abstract: Abstract: Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)
- AACR 2019 Poster: Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)
Early-Stage Cancer Minimal Residual Disease Detection
- Clinical Cancer Research: Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
- A Cancer Journal for Clinicians: Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring
- JCO Precision Oncology: Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies
- AACR 2022 Abstract: Multiomic, Plasma-Only Circulating Tumor DNA (ctDNA) Assay Identifies Breast Cancer Patients With Minimal Residual Disease (MRD) and Predicts Distant Recurrence
- Clinical Cancer Research: Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
- Clinical Cancer Research: Clinical impact of pre-surgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD1402 Trial
Advanced Cancer Treatment Selection
- NPJ Breast Cancer: Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer
- Cancer Research Communications: Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC
- Journal of the National Comprehensive Cancer Network: Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling
- Journal of Clinical Oncology: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
- JCO Precision Oncology: Association between availability of molecular genotyping results and overall survival in patients with advanced NSCLC
- Clinical Lung Cancer: Liquid Biopsy versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)
- JCO Precision Oncology: Impact of Simultaneous Circulating Tumor DNA and Tissue Genotyping in the Workup of Stage IV Lung Adenocarcinoma on Quality of Care in an Academic Community Medical Center
- JCO Precision Oncology: A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
- Cancer Discovery: Comutations and KRAS G12C inhibitor efficacy in advanced NSCLC
- JCO Precision Oncology: Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
- Clinical Cancer Research: The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
- JTO Clinical and Research Reports: Plasma genotyping at the time of diagnostic tissue biopsy decreases time to treatment in patients with advanced NSCLC – results from a prospective pilot study
- Frontiers in Oncology: Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
- Journal of Clinical Oncology: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- ESMO Open: Clinical Utility of Comprehensive Circulating Tumor DNA Genotyping Compared to Standard of Care Tissue Testing in Patients with Newly Diagnosed Metastatic Colorectal Cancer
- Clinical Lung Cancer: Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer
- European Journal of Cancer: Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
- British Journal of Cancer: Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
- Clinical Cancer Research: Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)
- JCO Precision Oncology: Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
- JCO Precision Oncology: Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer
- Clinical Cancer Research: Tumor tissue- versus plasma-based genotyping for selection of matched therapy and impact on clinical outcomes in patients with metastatic breast cancer
- Nature Medicine: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
- Lancet Oncology: Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- Journal of ImmunoTherapy of Cancer: Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
- Clinical Cancer Research: Routine Plasma-based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations Among Patients with Advanced Solid Tumors
- JAMA Oncology: Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-Line Treament of Metastatic NSCLC. The MYSTIC Phase 3 Randomized Clinical Trial
- Nature Medicine: Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- Cancer: Spectrum of Driver Mutations and Clinical Impact of Circulating Tumor DNA Analysis in Non–Small Cell Lung Cancer: Analysis of Over 8000 Cases
- Clinical Cancer Research: Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
- Clinical Cancer Research: Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer
- JCO Precision Oncology: Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
- New England Journal of Medicine: Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
- JCO Precision Oncology: Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series
- Clinical Cancer Research: The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- Journal of Thoracic Oncology: Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program
- Clinical Cancer Research: Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- Clinical Cancer Research: Cell-Free DNA and Circulating Tumor Cells:Comprehensive Liquid Biopsy Analysis inAdvanced Breast Cancer
- Cancer Discovery: Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- Clinical Lung Cancer: Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
- Clinical Cancer Research: Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
- Clinical Cancer Research: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung CancerPatients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- Oncotarget: MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
- Breast Cancer Res Treat: Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
- Oncotarget: Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
- PLOS One: Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Advanced Cancer Treatment Response
- Clinical Cancer Research: First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
- Clinical Cancer Research: A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer
- Cancer Cell: BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- Journal of Thoracic Oncology: Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer
- JCO Precision Oncology: Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
- NPJ Breast Cancer: Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
- Journal of Clinical Oncology: Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC
- Cancer Discovery: Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
- Journal of Clinical Oncology: Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC)
- Colorectal Cancer Facts & Figures. American Cancer Society. 2020-2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-2019.pdf. Accessed online June, 2021.
- Parikh A, Van Seventer E, Siravegna G, Hartwig A, et al. Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Clinical Cancer Research. April, 2021; 10.1158/1078-0432.CCR-21-0410
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies.
Furthermore, by clicking "Accept all", you are directing us to disclose your personal information to third parties for purposes of cross-contextual behavioral advertising. For more information, please refer to our privacy policy.
Manage consent
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.